The key catalyst is the year-end 2026 IND submission for NDV-01; any delay or FDA feedback will drive the next significant move. The 18-month durability data is supportive but preliminary. Monitor the Q4 2026 update for IND status and SPECTRUM enrollment initiation.
Drugs in focus
RLMD drug pipeline →NDV-01
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 2 completed; preparing for Phase 3 (SPECTRUM program)
- Time to market
- If the IND is cleared by early 2027 and Phase 3 SPECTRUM program proceeds smoothly, potential FDA submission could be 2029-2030, assuming positive pivotal data. The drug is still pre-Phase 3.
- Next catalyst
- None dated
What to watchThe next catalyst is the NDV-01 IND submission, which Relmada expects by year-end 2026 (about 6 weeks away). A successful IND clearance would allow the Phase 3 SPECTRUM program to begin, while any delay or FDA clinical hold would be sharply negative. The Q4 2026 corporate update will likely confirm the submission status.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $4.21entry
- T+1 · 20h ago −14.25%α −12.34% · $3.61
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Relmada reported Q3 2026 net loss of $13.9M ($0.12/share), wider than the $10.1M loss in Q3 2025, driven by increased R&D spending on NDV-01 and sepranolone trial preparation. The company highlighted positive 18-month Phase 2 durability data for NDV-01 in NMIBC and confirmed it remains on track to submit the NDV-01 IND by year-end 2026. Cash of $202.1M is expected to fund operations through 2029.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $13.9M ($0.12/share) vs $10.1M ($0.30/share) in Q3 2025
- R&D expense increased to $9.2M from $4.0M year-over-year due to NDV-01 and sepranolone preparation costs
- Cash, cash equivalents and short-term investments of $202.1M as of September 30, 2026
- NDV-01 CMC program on track for IND submission by year-end 2026
- 86% of evaluable 12-month complete responders remained in CR at 18 months in Phase 2 study
- Phase 3 program renamed SPECTRUM with two independent registrational pathways unchanged
- Sepranolone IND submission also on track for year-end 2026
Financial Impact
Net loss widened by $3.8M YoY; cash burn from operations was $12.6M in Q3 2026 vs $6.7M in Q3 2025
Risk Factors
- IND submission could be delayed beyond year-end 2026
- Phase 3 SPECTRUM program may not replicate Phase 2 efficacy or safety results
- Two BCG-naive patients progressed to muscle-invasive disease at Month 15, a potential safety signal
- Cash burn is accelerating as R&D spending increases for Phase 3 readiness
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-118933 |
| Document: ea031205701ex99-2.htm | 0001213900-26-118933 |
| Document: ea0312057-8k_relmada.htm | 0001213900-26-118933 |
| Document: 0001213900-26-118933-index-headers.html | 0001213900-26-118933 |
| Document: 0001213900-26-118933-index.html | 0001213900-26-118933 |
| Document: 0001213900-26-118933.txt | 0001213900-26-118933 |
| 8-K Data (Synthetic) | 0001213900-26-118933 |
Track record
11 reports on RLMD
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +38.81% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
- Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
- Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $4.21 Now $3.61 −14.25% settles Dec 14
- Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
- May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
- May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
- Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
- Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
- Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers